William Figg

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Platz Elizabeth A; Till Cathee; Goodman Phyllis J; Parnes Howard L; Figg William D; Albanes Demetrius; Neuhouser Marian L; Klein Eric A; Thompson Ian M; Kristal Alan R
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
Piekarz Richard L; Frye Robin; Turner Maria; Wright John J; Allen Steven L; Kirschbaum Mark H; Zain Jasmine; Prince H Miles; Leonard John P; Geskin Larisa J; Reeder Craig; Joske David; Figg William D; Gardner Erin R; Steinberg Seth M; Jaffe Elaine S; Stetler-Stevenson Maryalice; Lade Stephen; Fojo A Tito; Bates Susan E
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Pisle Stephen T; Figg William D
Antiandrogens in the 21st century.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of William Figg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Platz Elizabeth A; Till Cathee; Goodman Phyllis J; Parnes Howard L; Figg William D; Albanes Demetrius; Neuhouser Marian L; Klein Eric A; Thompson Ian M; Kristal Alan R
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(11):2807-13.
2009: Piekarz Richard L; Frye Robin; Turner Maria; Wright John J; Allen Steven L; Kirschbaum Mark H; Zain Jasmine; Prince H Miles; Leonard John P; Geskin Larisa J; Reeder Craig; Joske David; Figg William D; Gardner Erin R; Steinberg Seth M; Jaffe Elaine S; Stetler-Stevenson Maryalice; Lade Stephen; Fojo A Tito; Bates Susan E
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5410-7.
2009: Pisle Stephen T; Figg William D
Antiandrogens in the 21st century.
Cancer biology & therapy 2009;8(17):1611.
2009: Jain Lokesh; Vargo Craig A; Danesi Romano; Sissung Tristan M; Price Douglas K; Venzon David; Venitz Jürgen; Figg William D
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
Molecular cancer therapeutics 2009;8(9):2496-508.
2009: Cook Kristina M; Hilton Stephen T; Mecinovic Jasmin; Motherwell William B; Figg William D; Schofield Christopher J
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
The Journal of biological chemistry 2009;284(39):26831-8.
2009: Mucci Lorelei A; Stark Jennifer R; Figg William D; Schumacher Fredrick; Li Haojie; Abe Miyako; Hennessy Kristen; Stampfer Meir J; Gaziano John Michael; Ma Jing; Kantoff Philip W
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
International journal of cancer. Journal international du cancer 2009;125(5):1143-6.
2009: Russo Andrea L; Jedlicka Kimberly; Wernick Meredith; McNally Debbie; Kirk Melissa; Sproull Mary; Smith Sharon; Shankavaram Uma; Kaushal Aradhana; Figg William D; Dahut William; Citrin Deborah; Bottaro Donald P; Albert Paul S; Tofilon Philip J; Camphausen Kevin
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4292-8.
2009: English Bevin C; Price Douglas K; Figg William D
VEGF inhibition and metastasis: Possible implications for antiangiogenic therapy.
Cancer biology & therapy 2009;8(13):1212-3.
2009: Dahut William L; Aragon-Ching Jeanny B; Woo Sukyung; Tohnya Tanyifor M; Gulley James L; Arlen Philip M; Wright John J; Ventiz Jurgen; Figg William D
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Journal of clinical pharmacology 2009;49(6):650-60.
2009: Aragon-Ching Jeanny B; Jain Lokesh; Gulley James L; Arlen Philip M; Wright John J; Steinberg Seth M; Draper David; Venitz Jürgen; Jones Elizabeth; Chen Clara C; Figg William D; Dahut William L
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
BJU international 2009;103(12):1636-40.
2009: Therapontos Christina; Erskine Lynda; Gardner Erin R; Figg William D; Vargesson Neil
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(21):8573-8.
2009: Figg William D; Hussain Maha H; Gulley James L; Arlen Philip M; Aragon-Ching Jeanny B; Petrylak Daniel P; Higano Celestia S; Steinberg Seth M; Chatta Gurkamal S; Parnes Howard; Wright John J; Sartor Oliver; Dahut William L
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
The Journal of urology 2009;181(3):1104-13; discussion 1113.
2009: Aragon-Ching Jeanny B; Ning Yang-Min; Chen Clara C; Latham Lea; Guadagnini Jean-Pierre; Gulley James L; Arlen Philip M; Wright John J; Parnes Howard; Figg William D; Dahut William L
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Cancer investigation 2009;27(2):221-6.
2009: Woo Sukyung; Gardner Erin R; Chen Xiaohong; Ockers Sandra B; Baum Caitlin E; Sissung Tristan M; Price Douglas K; Frye Robin; Piekarz Richard L; Bates Susan E; Figg William D
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1496-503.
2009: Azad Nilofer S; Aragon-Ching Jeanny B; Dahut William L; Gutierrez Martin; Figg William D; Jain Lokesh; Steinberg Seth M; Turner Maria L; Kohn Elise C; Kong Heidi H
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1411-6.
2009: Danish Matthew; Gardner Erin R; Chen Xiaohong; Figg William D
Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(3):355-9.
2009: Gardner Erin R; Smith Nicola F; Figg William D; Sparreboom Alex
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
Journal of experimental & clinical cancer research : CR 2009;28():99.
2008: Sung Shian-Ying; Hsieh Chia-Ling; Law Andrew; Zhau Haiyen E; Pathak Sen; Multani Asha S; Lim Sharon; Coleman Ilsa M; Wu Li-Chin; Figg William D; Dahut William L; Nelson Peter; Lee Jae K; Amin Mahul B; Lyles Robert; Johnstone Peter A J; Marshall Fray F; Chung Leland W K
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.
Cancer research 2008;68(23):9996-10003.
2008: Gardner Erin R; Ahlers Christoph M; Shukla Suneet; Sissung Tristan M; Ockers Sandra B; Price Douglas K; Hamada Akinobu; Robey Robert W; Steinberg Seth M; Ambudkar Suresh V; Dahut William L; Figg William D
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU international 2008;102(11):1694-9.
2008: Di Lorenzo Giuseppe; Figg William D; Fossa Sophie D; Mirone Vincenzo; Autorino Riccardo; Longo Nicola; Imbimbo Ciro; Perdonà Sisto; Giordano Antonio; Giuliano Mario; Labianca Roberto; De Placido Sabino
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
European urology 2008;54(5):1089-94.
2008: Figg W D
The Pharm.D. investigator in clinical pharmacology: supply and demand.
Clinical pharmacology and therapeutics 2008;84(4):526-9.
2008: Chau Cindy H; Rixe Olivier; McLeod Howard; Figg William D
Validation of analytic methods for biomarkers used in drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):5967-76.
2008: Gulley James L; Aragon-Ching Jeanny B; Steinberg Seth M; Hussain Maha H; Sartor Oliver; Higano Celestia S; Petrylak Daniel P; Chatta Gurkamal S; Arlen Philip M; Figg William D; Dahut William L
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
The Journal of urology 2008;180(4):1432-7; discussion 1437.
2008: Chau Cindy H; Wang Weixin; Figg William D
Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis.
Cancer biology & therapy 2008;7(9):1386-7.
2008: Ge Yun; Byun Jung S; De Luca Paola; Gueron Geraldine; Yabe Idalia M; Sadiq-Ali Sara G; Figg William D; Quintero Jesse; Haggerty Cynthia M; Li Quentin Q; De Siervi Adriana; Gardner Kevin
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Molecular pharmacology 2008;74(3):872-83.
2008: Miles Robert J; Price Douglas K; Figg William D
Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer.
Cancer biology & therapy 2008;7(8):1180-1.
2008: Sharifi Nima; Dahut William L; Figg William D
The genetics of castration-resistant prostate cancer: what can the germline tell us?
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4691-3.
2008: Sharifi Nima; Hamada Akinobu; Sissung Tristan; Danesi Romano; Venzon David; Baum Caitlin; Gulley James L; Price Douglas K; Dahut William L; Figg William D
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU international 2008;102(5):617-21.
2008: Wang Weixin; Figg William D
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Cancer biology & therapy 2008;7(7):1004-5.
2008: Sissung Tristan M; Baum Caitlin E; Deeken John; Price Douglas K; Aragon-Ching Jeanny; Steinberg Seth M; Dahut William; Sparreboom Alex; Figg William D
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4543-9.
2008: Gardner Erin R; Dahut William L; Scripture Charity D; Jones Jacquin; Aragon-Ching Jeanny B; Desai Neil; Hawkins Michael J; Sparreboom Alex; Figg William D
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4200-5.
2008: Figg William D; Chau Cindy H; Okita Richard; Preusch Peter; Tracy Timothy S; McLeod Howard; Reed Michael; Pieper John; Knoell Daren; Miller Ken; Speedie Marilyn; Blouin Robert; Kroboth Patricia; Koda-Kimble Mary Anne; Taylor Palmer; Cohen Jordan; Giacomini Kathy
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research.
Pharmacotherapy 2008;28(7):821-33.
2008: Hamada Akinobu; Sissung Tristan; Price Douglas K; Danesi Romano; Chau Cindy H; Sharifi Nima; Venzon David; Maeda Kenji; Nagao Keisuke; Sparreboom Alex; Mitsuya Hiroaki; Dahut William L; Figg William D
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3312-8.
2008: Arlen Philip M; Bianco Fernando; Dahut William L; D'Amico Anthony; Figg William D; Freedland Stephen J; Gulley James L; Kantoff Philip W; Kattan Michael W; Lee Andrew; Regan Meredith M; Sartor Oliver;
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.
The Journal of urology 2008;179(6):2181-5; discussion 2185-6.
2008: Gao Rui; Price Douglas K; Sissung Tristan; Reed Eddie; Figg William D
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Molecular cancer therapeutics 2008;7(5):1246-50.
2008: Smith N F; Baker S D; Gonzalez F J; Harris J W; Figg W D; Sparreboom A
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
British journal of cancer 2008;98(10):1630-2.
2008: Hoque Ashraful; Goodman Phyllis; Ambrosone Christine B; Figg William D; Price Douglas K; Kopp William; Wu Xifeng; Conroy Jeffrey; Lehman Teresa A; Santella Regina M
Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.
Urology 2008;71(5):967-70.
2008: Chen Xiaohong; Gardner Erin R; Price Douglas K; Figg William D
Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis.
Journal of chromatographic science 2008;46(4):356-61.
2008: Chen Xiaohong; Gardner Erin R; Figg William D
Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;865(1-2):153-8.
2008: Li Haiqing; Raia Valentina; Bertolini Francesco; Price Douglas K; Figg William D
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
BJU international 2008;101(7):884-8.
2008: Danish Matthew; Sissung Tristan; Price Douglas K; Figg William D
Genetic stability of tumor microenvironment.
Cancer biology & therapy 2008;7(3):331-2.
2008: Scher Howard I; Halabi Susan; Tannock Ian; Morris Michael; Sternberg Cora N; Carducci Michael A; Eisenberger Mario A; Higano Celestia; Bubley Glenn J; Dreicer Robert; Petrylak Daniel; Kantoff Philip; Basch Ethan; Kelly William Kevin; Figg William D; Small Eric J; Beer Tomasz M; Wilding George; Martin Alison; Hussain Maha;
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1148-59.
2008: Gardner Erin R; Sparreboom Alex; Verweij Jaap; Figg William D
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.
Cancer biology & therapy 2008;7(3):412-5.
2008: Gardner Erin R; Dahut William; Figg William D
Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;862(1-2):213-8.
2008: Sharifi Nima; Dahut William L; Figg William D
Secondary hormonal therapy for prostate cancer: what lies on the horizon?
BJU international 2008;101(3):271-4.
2008: Jain Lokesh; Gardner Erin R; Venitz Jürgen; Dahut William; Figg William D
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Journal of pharmaceutical and biomedical analysis 2008;46(2):362-7.
2008: Sissung Tristan M; Danesi Romano; Price Douglas K; Steinberg Seth M; de Wit Ronald; Zahid Muhammad; Gaikwad Nilesh; Cavalieri Ercole; Dahut William L; Sackett Dan L; Figg William D; Sparreboom Alex
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Molecular cancer therapeutics 2008;7(1):19-26.
2008: Dahut William L; Scripture Charity; Posadas Edwin; Jain Lokesh; Gulley James L; Arlen Philip M; Wright John J; Yu Yunkai; Cao Liang; Steinberg Seth M; Aragon-Ching Jeanny B; Venitz Jürgen; Jones Elizabeth; Chen Clara C; Figg William D
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):209-14.
2008: Schrump David S; Fischette Maria R; Nguyen Dao M; Zhao Ming; Li Xinmin; Kunst Tricia F; Hancox Ana; Hong Julie A; Chen G Aaron; Kruchin Evgeny; Wright John J; Rosing Douglas R; Sparreboom Alex; Figg William D; Steinberg Seth M
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):188-98.
2008: Sissung Tristan M; Gardner Erin R; Gao Rui; Figg William D
Pharmacogenetics of membrane transporters: a review of current approaches.
Methods in molecular biology (Clifton, N.J.) 2008;448():41-62.
2007: Fine Howard A; Kim Lyndon; Albert Paul S; Duic J Paul; Ma Hilary; Zhang Wei; Tohnya Tanyifor; Figg William D; Royce Cheryl
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7101-6.
2007: Aragon-Ching Jeanny B; Gillespie John; Price Douglas K; Chuaqui Rodrigo; Rodriguez-Canales Jaime; Steinberg Seth M; Dahut William L; Figg William D
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
BJU international 2007;100(6):1245-8.
2007: Chen Xiaohong; Gardner Erin R; Gutierrez Martin; Kummar Shivaani; Figg William D
Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;858(1-2):302-6.
2007: Di Lorenzo Giuseppe; Autorino Riccardo; Perdonà Sisto; De Laurentiis Michele; D'Armiento Massimo; Cancello Giuseppe; Mirone Vincenzo; Imbimbo Ciro; Longo Nicola; Altieri Vincenzo; Tortora Gianpaolo; Figg William D; De Placido Sabino
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
European urology 2007;52(4):1020-7.
2007: Sharifi Nima; Figg William D
Androgen receptor modulation: lessons learned from beyond the prostate.
Cancer biology & therapy 2007;6(9):1358-9.
2007: Kummar Shivaani; Gutierrez Martin; Gardner Erin R; Donovan Erin; Hwang Kyunghwa; Chung Eun Joo; Lee Min-Jung; Maynard Kim; Kalnitskiy Mikhail; Chen Alice; Melillo Giovanni; Ryan Qin C; Conley Barbara; Figg William D; Trepel Jane B; Zwiebel James; Doroshow James H; Murgo Anthony J
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5411-7.
2007: Gills Joell J; Lopiccolo Jaclyn; Tsurutani Junji; Shoemaker Robert H; Best Carolyn J M; Abu-Asab Mones S; Borojerdi Jennifer; Warfel Noel A; Gardner Erin R; Danish Matthew; Hollander M Christine; Kawabata Shigeru; Tsokos Maria; Figg William D; Steeg Patricia S; Dennis Phillip A
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5183-94.
2007: Beverage Jacob N; Sissung Tristan M; Sion Amy M; Danesi Romano; Figg William D
CYP2D6 polymorphisms and the impact on tamoxifen therapy.
Journal of pharmaceutical sciences 2007;96(9):2224-31.
2007: Hamada Akinobu; Danesi Romano; Price Douglas K; Sissung Tristan; Chau Cindy; Venzon David; Sparreboom Alex; Dahut William L; Figg William D
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology 2007;70(2):217-20.
2007: Lakhani Nehal J; Sparreboom Alex; Xu Xia; Veenstra Timothy D; Venitz Jürgen; Dahut William L; Figg William D
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Journal of pharmaceutical sciences 2007;96(7):1821-31.
2007: Aragon-Ching Jeanny B; Li Haiqing; Gardner Erin R; Figg William D
Thalidomide analogues as anticancer drugs.
Recent patents on anti-cancer drug discovery 2007;2(2):167-74.
2007: Lal Suman; Wong Zee Wan; Jada Srinivasa Rao; Xiang Xiaoqiang; Chen Shu Xiao; Ang Peter Cher Siang; Figg William D; Lee Edmund Jd; Chowbay Balram
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Pharmacogenomics 2007;8(6):567-75.
2007: Li Haiqing; Price Douglas K; Figg William D
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer.
Anti-cancer drugs 2007;18(5):563-8.
2007: Figg William D; Li Haiqing; Sissung Tristan; Retter Avi; Wu Shenhong; Gulley James L; Arlen Phil; Wright John J; Parnes Howard; Fedenko Kathy; Latham Lea; Steinberg Seth M; Jones Elizabeth; Chen Clara; Dahut William
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
BJU international 2007;99(5):1047-55.
2007: Gojo Ivana; Jiemjit Anchalee; Trepel Jane B; Sparreboom Alex; Figg William D; Rollins Sandra; Tidwell Michael L; Greer Jacqueline; Chung Eun Joo; Lee Min-Jung; Gore Steven D; Sausville Edward A; Zwiebel James; Karp Judith E
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
2007: Al-Chalabi Tania; Figg William D
Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
Cancer biology & therapy 2007;6(3):318-9.
2007: Wu Shenhong L; Jones Elizabeth; Gulley James L; Arlen Philip M; Chen Clara C; Figg William D; Dahut William L
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
BJU international 2007;99(3):525-8.
2007: Deeken John F; Figg William D; Bates Susan E; Sparreboom Alex
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Anti-cancer drugs 2007;18(2):111-26.
2007: Smith N F; Marsh S; Scott-Horton T J; Hamada A; Mielke S; Mross K; Figg W D; Verweij J; McLeod H L; Sparreboom A
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Clinical pharmacology and therapeutics 2007;81(1):76-82.
2007: Di Lorenzo Giuseppe; Autorino Riccardo; Figg William D; De Placido Sabino
Hormone-refractory prostate cancer: where are we going?
Drugs 2007;67(8):1109-24.
2006: Ockers Sandra; Price Douglas K; Figg William D
DNA microarrays: tissue removal and processing affects gene expression.
Cancer biology & therapy 2006;5(12):1608-9.
2006: Ge Yun; Montano Idalia; Rustici Gabriella; Freebern Wendy J; Haggerty Cynthia M; Cui Wenwu; Ponciano-Jackson Damaris; Chandramouli G V R; Gardner Erin R; Figg William D; Abu-Asab Mones; Tsokos Maria; Jackson Sharon H; Gardner Kevin
Selective leukemic-cell killing by a novel functional class of thalidomide analogs.
Blood 2006;108(13):4126-35.
2006: Smith Erika K; Price Douglas K; Figg William D
Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation.
Cancer biology & therapy 2006;5(11):1443-4.
2006: Sissung Tristan M; Mross Klaus; Steinberg Seth M; Behringer Dirk; Figg William D; Sparreboom Alex; Mielke Stephan
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2893-6.
2006: Schrump David S; Fischette Maria R; Nguyen Dao M; Zhao Ming; Li Xinmin; Kunst Tricia F; Hancox Ana; Hong Julie A; Chen G Aaron; Pishchik Vitaliy; Figg William D; Murgo Anthony J; Steinberg Seth M
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5777-85.
2006: Figg William D; Ockers Sandra
Prostate cancer - 6th International Congress.
IDrugs : the investigational drugs journal 2006;9(10):675-8.
2006: Parnes Howard L; Figg William D
Chemoprevention in prostate cancer.
Pharmacotherapy 2006;26(10):1533; author reply 1533.
2006: Jain Lokesh; Venitz Jürgen; Figg William D
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Cancer biology & therapy 2006;5(10):1270-2.
2006: Beverage Jacob N; Figg William D
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator.
Cancer biology & therapy 2006;5(9):1094-5.
2006: Lakhani Nehal; Sparreboom Alex; Venitz Jürgen; Dahut William L; Figg William D
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anti-cancer drugs 2006;17(8):977-83.
2006: Acharya Milin R; Karp Judith E; Sausville Edward A; Hwang Kyunghwa; Ryan Qin; Gojo Ivana; Venitz Jurgen; Figg William D; Sparreboom Alex
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
2006: Sion Amy M; Figg William D
Lysyl oxidase (LOX) and hypoxia-induced metastases.
Cancer biology & therapy 2006;5(8):909-11.
2006: Lepper Erin R; Smith Nicola F; Cox Michael C; Scripture Charity D; Figg William D
Thalidomide metabolism and hydrolysis: mechanisms and implications.
Current drug metabolism 2006;7(6):677-85.
2006: Cox Michael C; Low Jennifer; Lee James; Walshe Janice; Denduluri Neelima; Berman Arlene; Permenter Matthew G; Petros William P; Price Douglas K; Figg William D; Sparreboom Alex; Swain Sandra M
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4636-40.
2006: Gardner Erin R; Burger Herman; van Schaik Ron H; van Oosterom Allan T; de Bruijn Ernst A; Guetens Gunther; Prenen Hans; de Jong Floris A; Baker Sharyn D; Bates Susan E; Figg William D; Verweij Jaap; Sparreboom Alex; Nooter Kees
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
2006: Figg William D; Chau Cindy H
Heterogeneity in drug disposition determines interindividual variability of docetaxel pharmacokinetics.
Cancer biology & therapy 2006;5(7):840-1.
2006: Ng Sylvia S W; Sparreboom Alex; Shaked Yuval; Lee Christina; Man Shan; Desai Neil; Soon-Shiong Patrick; Figg William D; Kerbel Robert S
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4331-8.
2006: Scripture Charity D; Figg William D
Drug interactions in cancer therapy.
Nature reviews. Cancer 2006;6(7):546-58.
2006: Warfel Noel A; Lepper Erin R; Zhang Chunyu; Figg William D; Dennis Phillip A
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3502-9.
2006: Figg William D; Dunn Lara; Liewehr David J; Steinberg Seth M; Thurman Paul W; Barrett J Carl; Birkinshaw Julian
Scientific collaboration results in higher citation rates of published articles.
Pharmacotherapy 2006;26(6):759-67.
2006: Cox Michael C; Dahut William L; Figg William D
The use of thalidomide in androgen-independent prostate cancer.
Urologic oncology 2006;24(3):246-9.
2006: Scripture Charity D; Figg William D; Sparreboom Alex
Peripheral neuropathy induced by Paclitaxel: recent insights and future perspectives.
Current neuropharmacology 2006;4(2):165-72.
2006: Sparreboom Alex; Figg William D
Identifying sources of interindividual pharmacokinetic variability with population modeling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1951-3.
2006: Ahlers Christoph M; Figg William D
ETS-TMPRSS2 fusion gene products in prostate cancer.
Cancer biology & therapy 2006;5(3):254-5.
2006: Sissung Tristan M; Price Douglas K; Sparreboom Alex; Figg William D
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Molecular cancer research : MCR 2006;4(3):135-50.
2006: Singh Arun S; Macpherson Gordon R; Price Douglas K; Schimel Daniel; Figg William D
Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Oncology reports 2006;15(3):519-24.
2006: Smith Nicola F; Figg William D; Sparreboom Alex
Pharmacogenetics of irinotecan metabolism and transport: an update.
Toxicology in vitro : an international journal published in association with BIBRA 2006;20(2):163-75.
2006: Scripture Charity D; Figg William D; Sparreboom Alex
The role of drug-metabolising enzymes in clinical responses to chemotherapy.
Expert opinion on drug metabolism & toxicology 2006;2(1):17-25.
2006: Acharya Milin R; Sparreboom Alex; Sausville Edward A; Conley Barbara A; Doroshow James H; Venitz Jurgen; Figg William D
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
2006: Figg William D
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Clinical pharmacology and therapeutics 2006;79(1):1-8.
2006: Dahut William L; Lakhani Nehal J; Gulley James L; Arlen Philip M; Kohn Elise C; Kotz Herbert; McNally Debbie; Parr Allyson; Nguyen Diana; Yang Sherry X; Steinberg Seth M; Venitz Jürgen; Sparreboom Alex; Figg William D
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer biology & therapy 2006;5(1):22-7.
2006: Rozhansky Flora; Chen Ming-Hui; Cox Michael C; Dahut William; Figg William D; D'Amico Anthony V
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
Cancer 2006;106(1):63-7.
2006: Hwang Kyunghwa; Scripture Charity D; Gutierrez Martin; Kummar Shivaani; Figg William D; Sparreboom Alex
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;830(1):35-40.
2006: Gardner Erin R; Liau Chi-Ting; Chu Zyting E; Figg William D; Sparreboom Alex
Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(14):2170-4.
2005: Longoria Ritchie L; Cox Michael C; Figg William D
Antiangiogenesis: a possible treatment option for prostate cancer?
Clinical genitourinary cancer 2005;4(3):197-202.
2005: Luzzio Frederick A; Duveau Damien Y; Lepper Erin R; Figg William D
Synthesis of racemic cis-5-hydroxy-3-phthalimidoglutarimide. A metabolite of thalidomide isolated from human plasma.
The Journal of organic chemistry 2005;70(24):10117-20.
2005: Sharifi Nima; Dahut William L; Steinberg Seth M; Figg William D; Tarassoff Christopher; Arlen Philip; Gulley James L
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
BJU international 2005;96(7):985-9.
2005: Chau Cindy H; Permenter Matthew G; Steinberg Seth M; Retter Avi S; Dahut William L; Price Douglas K; Figg William D
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
Cancer biology & therapy 2005;4(11):1222-5.
2005: Smith Nicola F; Figg William D; Sparreboom Alex
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
Expert opinion on drug metabolism & toxicology 2005;1(3):429-45.
2005: Lepper Erin R; Baker Sharyn D; Permenter Matt; Ries Nicole; van Schaik Ron H N; Schenk Paul W; Price Douglas K; Ahn Danielle; Smith Nicola F; Cusatis George; Ingersoll Roxann G; Bates Susan E; Mathijssen Ron H J; Verweij Jaap; Figg William D; Sparreboom Alex
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7398-404.
2005: Best Carolyn J M; Gillespie John W; Yi Yajun; Chandramouli Gadisetti V R; Perlmutter Mark A; Gathright Yvonne; Erickson Heidi S; Georgevich Lauren; Tangrea Michael A; Duray Paul H; González Sergio; Velasco Alfredo; Linehan W Marston; Matusik Robert J; Price Douglas K; Figg William D; Emmert-Buck Michael R; Chuaqui Rodrigo F
Molecular alterations in primary prostate cancer after androgen ablation therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6823-34.
2005: Scripture Charity D; Sparreboom Alex; Figg William D
Modulation of cytochrome P450 activity: implications for cancer therapy.
The lancet oncology 2005;6(10):780-9.
2005: Posadas Edwin M; Gulley James; Arlen Philip M; Trout Alisa; Parnes Howard L; Wright John; Lee Min-Jung; Chung Eun Joo; Trepel Jane B; Sparreboom Alex; Chen Clara; Jones Elizabeth; Steinberg Seth M; Daniels Andrew; Figg William D; Dahut William L
A phase II study of perifosine in androgen independent prostate cancer.
Cancer biology & therapy 2005;4(10):1133-7.
2005: Acharya Milin R; Sparreboom Alex; Venitz Jürgen; Figg William D
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Molecular pharmacology 2005;68(4):917-32.
2005: D'Amico Anthony V; Chen Ming-Hui; Cox Michael C; Dahut William; Figg William D
Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
Urology 2005;66(3):571-6.
2005: Singh Arun S; Figg William D
In vivo models of prostate cancer metastasis to bone.
The Journal of urology 2005;174(3):820-6.
2005: Smith Nicola F; Acharya Milin R; Desai Neil; Figg William D; Sparreboom Alex
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
Cancer biology & therapy 2005;4(8):815-8.
2005: Tkacz Victoria L; Tohnya Tanyifor M; Figg William D
Cyclooxygenase-2 and angiogenesis in prostate cancer.
Cancer biology & therapy 2005;4(8):813-4.
2005: Cox Michael C; Scripture Charity D; Figg William D
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Expert review of anticancer therapy 2005;5(4):605-11.
2005: Scripture Charity D; Figg William D; Sparreboom Alex
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
Therapeutics and clinical risk management 2005;1(2):107-14.
2005: Sparreboom Alex; Scripture Charity D; Trieu Vuong; Williams Paul J; De Tapas; Yang Andrew; Beals Bridget; Figg William D; Hawkins Michael; Desai Neil
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4136-43.
2005: Sparreboom Alex; Loos Walter J; Burger Herman; Sissung Tristan M; Verweij Jaap; Figg William D; Nooter Kees; Gelderblom Hans
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
2005: Ryan Qin C; Headlee Donna; Acharya Milin; Sparreboom Alex; Trepel Jane B; Ye Joseph; Figg William D; Hwang Kyunghwa; Chung Eun Joo; Murgo Anthony; Melillo Giovanni; Elsayed Yusri; Monga Manish; Kalnitskiy Mikhail; Zwiebel James; Sausville Edward A
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
2005: Scripture Charity D; Szebeni Janos; Loos Walter J; Figg William D; Sparreboom Alex
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer biology & therapy 2005;4(5):555-60.
2005: Pingpank James F; Libutti Steven K; Chang Richard; Wood Bradford J; Neeman Ziv; Kam Anthony W; Figg William D; Zhai Souping; Beresneva Tatiana; Seidel Geoffrey D; Alexander H Richard
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3465-74.
2005: Cox Michael C; Permenter Matthew; Figg William D
Angiogenesis and prostate cancer: important laboratory and clinical findings.
Current oncology reports 2005;7(3):215-9.
2005: Gulley James L; Figg William D; Steinberg Seth M; Carter Jane; Sartor Oliver; Higano Celestia S; Petrylak Daniel P; Chatta Gerkamal; Hussain Maha H; Dahut William L
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
The Journal of urology 2005;173(5):1567-71.
2005: Fuse Eiichi; Kuwabara Takashi; Sparreboom Alex; Sausville Edward A; Figg William D
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Journal of clinical pharmacology 2005;45(4):394-403.
2005: Lepper Erin R; Nooter Kees; Verweij Jaap; Acharya Milin R; Figg William D; Sparreboom Alex
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Pharmacogenomics 2005;6(2):115-38.
2005: Figg William D; Liu Yinong; Arlen Philip; Gulley James; Steinberg Seth M; Liewehr David J; Cox Michael C; Zhai Suoping; Cremers Serge; Parr Allyson; Yang Xiaowei; Chen Clara C; Jones Elizabeth; Dahut William L
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
The Journal of urology 2005;173(3):790-6.
2005: Singh Arun S; Chau Cindy H; Price Douglas K; Figg William D
Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.
Nature clinical practice. Urology 2005;2(2):101-7.
2005: Chau Cindy H; Figg William D
Molecular and phenotypic heterogeneity of metastatic prostate cancer.
Cancer biology & therapy 2005;4(2):166-7.
2005: Baker Sharyn D; Li Jing; ten Tije Albert J; Figg William D; Graveland Wilfried; Verweij Jaap; Sparreboom Alex
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clinical pharmacology and therapeutics 2005;77(1):43-53.
2005: Lakhani Nehal J; Lepper Erin R; Sparreboom Alex; Dahut William L; Venitz Jürgen; Figg William D
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(9):1176-82.
2004: Ng Sylvia S W; Figg William D
Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy.
Cancer biology & therapy 2004;3(12):1212-3.
2004: Macpherson Gordon R; Singh Arun S; Bennett Charles L; Venzon David J; Liewehr David J; Franks Michael E; Dahut William L; Kantoff Philip W; Price Douglas K; Figg William D
Genotyping and functional analysis of the D104N variant of human endostatin.
Cancer biology & therapy 2004;3(12):1298-303.
2004: Figg William D; Franks Michael E; Venzon David; Duray Paul; Cox Michael C; Linehan W Marston; Van Bingham W; Eastham James A; Reed Eddie; Sartor Oliver
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
World journal of urology 2004;22(6):425-30.
2004: Tohnya Tanyifor M; Figg William D
Immunomodulation of multiple myeloma.
Cancer biology & therapy 2004;3(11):1060-1.
2004: Mathijssen Ron H J; de Jong Floris A; van Schaik Ron H N; Lepper Erin R; Friberg Lena E; Rietveld Trinet; de Bruijn Peter; Graveland Wilfried J; Figg William D; Verweij Jaap; Sparreboom Alex
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
2004: Tohnya Tanyifor M; Hwang Kyunghwa; Lepper Erin R; Fine Howard A; Dahut William L; Venitz Jürgen; Sparreboom Alex; Figg William D
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):135-41.
2004: Sparreboom Alex; Chen Huachen; Acharya Milin R; Senderowicz Adrian M; Messmann Richard A; Kuwabara Takashi; Venzon David J; Murgo Anthony J; Headlee Donna; Sausville Edward A; Figg William D
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
2004: Hwang Kyunghwa; Piekarz Richard L; Bates Susan E; Figg William D; Sparreboom Alex
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(1):81-6.
2004: Tan Antoinette R; Yang Xiaowei; Berman Arlene; Zhai Suoping; Sparreboom Alex; Parr Allyson L; Chow Catherine; Brahim Jaime S; Steinberg Seth M; Figg William D; Swain Sandra M
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5038-47.
2004: Paoluzzi Luca; Singh Arun S; Price Douglas K; Danesi Romano; Mathijssen Ron H J; Verweij Jaap; Figg William D; Sparreboom Alex
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Journal of clinical pharmacology 2004;44(8):854-60.
2004: Tan Antoinette R; Yang Xiaowei; Hewitt Stephen M; Berman Arlene; Lepper Erin R; Sparreboom Alex; Parr Allyson L; Figg William D; Chow Catherine; Steinberg Seth M; Bacharach Stephen L; Whatley Millie; Carrasquillo Jorge A; Brahim Jaime S; Ettenberg Seth A; Lipkowitz Stan; Swain Sandra M
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3080-90.
2004: Acharya Milin R; Figg William D
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Cancer biology & therapy 2004;3(8):719-20.
2004: Acharya Milin R; Baker Sharyn D; Verweij Jaap; Figg William D; Sparreboom Alex
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Analytical biochemistry 2004;331(1):192-4.
2004: Bates Susan E; Bakke Susan; Kang Min; Robey Robert W; Zhai Suoping; Thambi Paul; Chen Clara C; Patil Sheela; Smith Tom; Steinberg Seth M; Merino Maria; Goldspiel Barry; Meadows Beverly; Stein Wilfred D; Choyke Peter; Balis Frank; Figg William D; Fojo Tito
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4724-33.
2004: Dahut William L; Gulley James L; Arlen Philip M; Liu Yinong; Fedenko Katherine M; Steinberg Seth M; Wright John J; Parnes Howard; Chen Clara C; Jones Elizabeth; Parker Catherine E; Linehan W Marston; Figg William D
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2532-9.
2004: Lepper Erin R; Hicks J Kevin; Verweij Jaap; Zhai Suoping; Figg William D; Sparreboom Alex
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):305-10.
2004: Lakhani Nehal J; Sparreboom Alex; Dahut William L; Venitz Jürgen; Figg William D
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):289-93.
2004: Paoluzzi Luca; Figg William D
Histone deacetylase inhibitors are potent radiation protectants.
Cancer biology & therapy 2004;3(7):612-3.
2004: Acharya Milin R; Venitz Jürgen; Figg William D; Sparreboom Alex
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004;7(3):195-208.
2004: Ng Sylvia S W; MacPherson Gordon R; Gütschow Michael; Eger Kurt; Figg William D
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4192-7.
2004: Macpherson Gordon R; Figg William D
Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade.
Cancer biology & therapy 2004;3(6):503-4.
2004: Sparreboom Alex; Cox Michael C; Acharya Milin R; Figg William D
Herbal remedies in the United States: potential adverse interactions with anticancer agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2489-503.
2004: Price Douglas K; Figg William D
hTert-immortalized endothelial cells: an important new research tool.
Cell cycle (Georgetown, Tex.) 2004;3(6):789.
2004: Tohnya Tanyifor M; Kim Sonia; Fine Howard A; Dunn Lara; Figg William D; Sparreboom Alex
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;805(1):135-40.
2004: Price Douglas K; Figg William D
Mutations in the EGFR: the importance of genotyping.
Cancer biology & therapy 2004;3(5):434-5.
2004: Franks Michael E; Macpherson Gordon R; Figg William D
Thalidomide.
Lancet 2004;363(9423):1802-11.
2004: Hwang Kyunghwa; Acharya Milin R; Sausville Edward A; Zhai Suoping; Woo Eunhee W; Venitz Jürgen; Figg William D; Sparreboom Alex
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
2004: Lepper Erin R; Ng Sylvia S W; Gütschow Michael; Weiss Michael; Hauschildt Sunna; Hecker Thomas K; Luzzio Frederick A; Eger Kurt; Figg William D
Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
Journal of medicinal chemistry 2004;47(9):2219-27.
2004: Tohnya Tanyifor M; Ng Sylvia S W; Dahut William L; Wright John J; Arlen Philip M; Gulley James L; Parker Catherine; Zeldis Jerome; Figg William D
A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
Clinical prostate cancer 2004;2(4):241-3.
2004: Cox Michael C; Figg William D; Thurman Paul W
No rational theory for drug pricing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):962-3.
2004: McDonald Donald M; Teicher Beverly A; Stetler-Stevenson William; Ng Sylvia S W; Figg William D; Folkman Judah; Hanahan Douglas; Auerbach Robert; O'Reilly Michael; Herbst Roy; Cheresh David; Gordon Michael; Eggermont Alexander; Libutti Steven K
Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(2):161-75.
2004: Singh Arun; Figg William D
Upregulation of the androgen receptor during prostate cancer progression.
Cancer biology & therapy 2004;3(3):284-5.
2004: Ng Sylvia S W; Figg William D; Sparreboom Alex
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Cancer research 2004;64(3):821-4.
2004: Chan Linda W; Moses Marsha A; Goley Elizabeth; Sproull Mary; Muanza Thierry; Coleman C Norman; Figg William D; Albert Paul S; Ménard Cynthia; Camphausen Kevin
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):499-506.
2004: Price Douglas K; Franks Michael E; Figg William D
Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
The Journal of urology 2004;171(2 Pt 2):S45-9; discussion S49.
2003: Retter Avi S; Figg William D; Dahut William L
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Clinical prostate cancer 2003;2(3):153-9.
2003: Franks Michael E; Macpherson Gordon R; Lepper Erin R; Figg William D; Sparreboom Alex
New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(6):301-12.
2003: Lakhani Nehal J; Venitz Jürgen; Figg William D; Sparreboom Alex
Pharmacogenetics of estrogen metabolism and transport in relation to cancer.
Current drug metabolism 2003;4(6):505-13.
2003: Hussain Mahrukh M; Kotz Herbert; Minasian Lori; Premkumar Ahalya; Sarosy Gisele; Reed Eddie; Zhai Suoping; Steinberg Seth M; Raggio Miranda; Oliver Vyta Kulpa; Figg William D; Kohn Elise C
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4356-63.
2003: Figg William D; Cox Michael C
Pharmacy education: back to the basics?
Pharmacotherapy 2003;23(11):1381-90.
2003: Ten Tije Albert J; Loos Walter J; Verweij Jaap; Baker Sharyn D; Dinh Kimberly; Figg William D; Sparreboom Alex
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
2003: Lepper Erin R; Swain Sandra M; Tan Antoinette R; Figg William D; Sparreboom Alex
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):181-8.
2003: Rudek Michelle A; Bauer Kenneth S; Lush Richard M; Stinson Sherman F; Senderowicz Adrian M; Headlee Donna J; Arbuck Susan G; Cox Michael C; Murgo Anthony J; Sausville Edward A; Figg William D
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
2003: Rudek Michelle A; Venitz Jürgen; Ando Yuichi; Reed Eddie; Pluda James M; Figg William D
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Journal of clinical pharmacology 2003;43(10):1124-35.
2003: Ng Sylvia S; Figg William D
Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice.
Anticancer research 2003;23(5A):3585-90.
2003: Macpherson Gordon R; Ng Sylvia S W; Forbes Siiri L; Melillo Giovanni; Karpova Tatiana; McNally James; Conrads Thomas P; Veenstra Timothy D; Martinez Alfredo; Cuttitta Frank; Price Douglas K; Figg William D
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Molecular cancer therapeutics 2003;2(9):845-54.
2003: Passaro Maureen D; Piquion Johann; Mullen Nancy; Sutherland Dorette; Zhai Suoping; Figg William D; Blye Richard; Nieman Lynnette K
Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women.
Human reproduction (Oxford, England) 2003;18(9):1820-7.
2003: Luzzio Frederick A; Mayorov Alexander V; Ng Sylvia S W; Kruger Erwin A; Figg William D
Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
Journal of medicinal chemistry 2003;46(18):3793-9.
2003: Macpherson Gordon R; Franks Michael; Tomoaia-Cotisel Andrada; Ando Yuichi; Price Douglas K; Figg William D
Current status of thalidomide and its role in the treatment of metastatic prostate cancer.
Critical reviews in oncology/hematology 2003;46 Suppl():S49-57.
2003: Ng Sylvia S W; Gütschow Michael; Weiss Michael; Hauschildt Sunna; Teubert Uwe; Hecker Thomas K; Luzzio Frederick A; Kruger Erwin A; Eger Kurt; Figg William D
Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Cancer research 2003;63(12):3189-94.
2003: Fine Howard A; Wen Patrick Y; Maher Elizabeth A; Viscosi Elene; Batchelor Tracy; Lakhani Nehal; Figg William D; Purow Benjamin W; Borkowf Craig B
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(12):2299-304.
2003: Sparreboom Alex; Danesi Romano; Ando Yuichi; Chan Juliana; Figg William D
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(2):71-84.
2003: Kurdziel Karen A; Figg William D; Carrasquillo Jorge A; Huebsch Susan; Whatley Millie; Sellers David; Libutti Steven K; Pluda James M; Dahut William; Reed Edward; Bacharach Stephen L
Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2003;5(2):86-93.
2003: Horne McDonald K; Figg William D; Arlen Phil; Gulley James; Parker Catherine; Lakhani Nehal; Parnes Howard; Dahut William L
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Pharmacotherapy 2003;23(3):315-8.
2003: Lakhani Nehal J; Sarkar Mohamadi A; Venitz Jurgen; Figg William D
2-Methoxyestradiol, a promising anticancer agent.
Pharmacotherapy 2003;23(2):165-72.
2003: Messmann Richard A; Ullmann Claudio Dansky; Lahusen Tyler; Kalehua Audrey; Wasfy Jason; Melillo Giovanni; Ding Ivan; Headlee Donna; Figg William D; Sausville Edward A; Senderowicz Adrian M
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):562-70.
2003: Zhai Suoping; Sausville Edward A; Senderowicz Adrian M; Ando Yuichi; Headlee Donna; Messmann Richard A; Arbuck Susan; Murgo Anthony J; Melillo Giovanni; Fuse Eiichi; Figg William D
Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anti-cancer drugs 2003;14(2):125-35.
2003: Gulley James; Figg William D; Dahut William L
Treatment options for androgen-independent prostate cancer.
Clinical advances in hematology & oncology : H&O 2003;1(1):49-57.
2003: Uchio Edward M; Linehan W Marston; Figg William D; Walther McClellan M
A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
The Journal of urology 2003;169(1):357-60.
2003: Leonard Gregory D; Dahut William L; Gulley James L; Arlen Philip M; Figg William D
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer.
Reviews in urology 2003;5 Suppl 3():S65-70.
2003: Hamilton Michael; Dahut William; Brawley Otis; Davis Patricia; Wells-Jones Toni; Kohler David; Duray Paul; Liewehr David J; Lakhani Nehal; Steinberg Seth M; Figg William D; Reed Eddie
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
Acta oncologica (Stockholm, Sweden) 2003;42(3):195-201.
2002: Arlen Philip M; Figg William D; Gulley James; Cox Michael C; Linehan W Marston; Dahut William
National Cancer Institute intramural approach to advanced prostate cancer.
Clinical prostate cancer 2002;1(3):153-62.
2002: Schrump David S; Nguyen Dao M; Kunst Tricia E; Hancox Ana; Figg William D; Steinberg Seth M; Pishchik Vitality; Becerra Yvonne
Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura.
Clinical lung cancer 2002;4(3):186-92.
2002: Ando Yuichi; Price Douglas K; Dahut William L; Cox Michael C; Reed Eddie; Figg William D
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer biology & therapy 2002;1(6):669-73.
2002: Marshall John L; Rizvi Naiyer; Kauh John; Dahut William; Figuera Manuela; Kang Min H; Figg William D; Wainer Irving; Chaissang Christoff; Li Megan Zhaoyang; Hawkins Michael J
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.
Journal of experimental therapeutics & oncology 2002;2(6):325-32.
2002: Tan Antoinette R; Headlee Donna; Messmann Richard; Sausville Edward A; Arbuck Susan G; Murgo Anthony J; Melillo Giovanni; Zhai Suoping; Figg William D; Swain Sandra M; Senderowicz Adrian M
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4074-82.
2002: Zogakis T G; Costouros N G; Kruger E A; Forbes S; He M; Qian M; Feldman A L; Figg W D; Alexander H R; Liu E T; Kohn E C; Libutti S K
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.
BioTechniques 2002;33(3):664-6, 668, 670.
2002: Zhai Suoping; Sausville Edward; Figg William D
A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
Biomedical chromatography : BMC 2002;16(6):379-82.
2002: Bennett Charles L; Price Douglas K; Kim Simon; Liu Dachao; Jovanovic Borko D; Nathan Derek; Johnson Margaret E; Montgomery Jeffrey S; Cude Kelly; Brockbank Justin C; Sartor Oliver; Figg William D
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(17):3599-604.
2002: Blagosklonny Mikhail V; Darzynkiewicz Zbigniew; Figg William D
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.
Cancer biology & therapy 2002;1(4):420-5.
2002: Ng S S W; Brown M; Figg W D
Thalidomide, an antiangiogenic agent with clinical activity in cancer.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2002;56(4):194-9.
2002: Rudek Michelle A; Venitz Jürgen; Figg William D
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Pharmacotherapy 2002;22(6):705-20.
2002: Ando Yuichi; Fuse Eiichi; Figg William D
Thalidomide metabolism by the CYP2C subfamily.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1964-73.
2002: Kaur Maninderjeet; Reed Eddie; Sartor Oliver; Dahut William; Figg William D
Suramin's development: what did we learn?
Investigational new drugs 2002;20(2):209-19.
2002: Figg William D; Kruger Erwin A; Price Douglas K; Kim Sonia; Dahut William D
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Investigational new drugs 2002;20(2):183-94.
2002: Ando Yuichi; Figg William D
Irinotecan in small-cell lung cancer.
The New England journal of medicine 2002;346(18):1414-5; author reply 1414-5.
2002: Zhai Suoping; Senderowicz Adrian M; Sausville Edward A; Figg William D
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
The Annals of pharmacotherapy 2002;36(5):905-11.
2002: Schrump David S; Zhai Suoping; Nguyen Dao M; Weiser Todd S; Fisher Bradley A; Terrill Richard E; Flynn Bernard M; Duray Paul H; Figg William D
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques.
The Journal of thoracic and cardiovascular surgery 2002;123(4):686-94.
2002: Béliveau Richard; Gingras Denis; Kruger Erwin A; Lamy Sylvie; Sirois Pierre; Simard Bryan; Sirois Martin G; Tranqui Leone; Baffert Fabienne; Beaulieu Edith; Dimitriadou Violetta; Pépin Marie-Claude; Courjal Frank; Ricard Isabelle; Poyet Patrick; Falardeau Pierre; Figg William D; Dupont Eric
The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1242-50.
2002: Gore Steven D; Weng Li-Jun; Figg William D; Zhai Suoping; Donehower Ross C; Dover George; Grever Michael R; Griffin Constance; Grochow Louise B; Hawkins Anita; Burks Kathleen; Zabelena Yelena; Miller Carole B
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):963-70.
2002: Sandor Victor; Bakke Susan; Robey Robert W; Kang Min H; Blagosklonny Mikhail V; Bender Jonathon; Brooks Rebecca; Piekarz Richard L; Tucker Eben; Figg William D; Chan Kenneth K; Goldspiel Barry; Fojo Antonio Tito; Balcerzak Stanley P; Bates Susan E
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):718-28.
2002: Price Douglas K; Ando Yuichi; Kruger Erwin A; Weiss Michael; Figg William D
5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
Therapeutic drug monitoring 2002;24(1):104-10.
2002: Neelapu Sattva; Figg William D; Dahut William; Reed Eddie
Leptomeningeal carcinomatosis in metastatic prostate cancer.
Southern medical journal 2002;95(1):107-8.
2002: Cianfrocca Mary; Cooley Timothy P; Lee Jeannette Y; Rudek Michelle A; Scadden David T; Ratner Lee; Pluda James M; Figg William D; Krown Susan E; Dezube Bruce J
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):153-9.
2002: Macpherson Gordon R; Ng Sylvia S W; Lakhani Nehal J; Price Douglas K; Venitz Jurgen; Figg William D
Antiangiogenesis therapeutic strategies in prostate cancer.
Cancer metastasis reviews 2002;21(1):93-106.
2002: Bates Susan F; Chen Clara; Robey Robert; Kang Min; Figg William D; Fojo Tito
Reversal of multidrug resistance: lessons from clinical oncology.
Novartis Foundation symposium 2002;243():83-96; discussion 96-102, 180-5.
2002: Cude Kelly J; Montgomery Jeffrey S; Price Douglas K; Dixon Shannon C; Kincaid Randall L; Kovacs Karl F; Venzon David J; Liewehr David J; Johnson Margaret E; Reed Eddie; Figg William D
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
Urologia internationalis 2002;68(1):16-23.
2001: Kruger E A; Duray P H; Price D K; Pluda J M; Figg W D
Approaches to preclinical screening of antiangiogenic agents.
Seminars in oncology 2001;28(6):570-6.
2001: Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg W D; Fojo T
A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Cancer 2001;92(6):1577-90.
2001: Montgomery J S; Price D K; Figg W D
The androgen receptor gene and its influence on the development and progression of prostate cancer.
The Journal of pathology 2001;195(2):138-46.
2001: Carrasquillo J A; Whatley M; Dyer V; Figg W D; Dahut W
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(9):1359-63.
2001: Figg W D; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger E A; Pluda J; Dahut W L
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Seminars in oncology 2001;28(4 Suppl 15):62-6.
2001: Woo E W; Messmann R; Sausville E A; Figg W D
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(2):247-57.
2001: Chang E; Alexander H R; Libutti S K; Hurst R; Zhai S; Figg W D; Bartlett D L
Laparoscopic continuous hyperthermic peritoneal perfusion.
Journal of the American College of Surgeons 2001;193(2):225-9.
2001: Gore S D; Weng L J; Zhai S; Figg W D; Donehower R C; Dover G J; Grever M; Griffin C A; Grochow L B; Rowinsky E K; Zabalena Y; Hawkins A L; Burks K; Miller C B
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2330-9.
2001: Gilbert J; Baker S D; Bowling M K; Grochow L; Figg W D; Zabelina Y; Donehower R C; Carducci M A
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2292-300.
2001: Molloy F M; Floeter M K; Syed N A; Sandbrink F; Culcea E; Steinberg S M; Dahut W; Pluda J; Kruger E A; Reed E; Figg W D
Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Muscle & nerve 2001;24(8):1050-7.
2001: Figg W D; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg S M; Jones E; Premkumar A; Linehan W M; Floeter M K; Chen C C; Dixon S; Kohler D R; Krüger E A; Gubish E; Pluda J M; Reed E
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1888-93.
2001: Krüger E A; Figg W D
Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1867-72.
2001: Kang M H; Figg W D; Ando Y; Blagosklonny M V; Liewehr D; Fojo T; Bates S E
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1610-7.
2001: Kohn E C; Reed E; Sarosy G A; Minasian L; Bauer K S; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg W D; Liotta L A
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1600-9.
2001: Rudek M A; Horne M; Figg W D; Dahut W; Dyer V; Pluda J M; Reed E
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
American journal of hematology 2001;67(1):51-3.
2001: Sausville E A; Arbuck S G; Messmann R; Headlee D; Bauer K S; Lush R M; Murgo A; Figg W D; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz A M
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2319-33.
2001: Ghate J V; Turner M L; Rudek M A; Figg W D; Dahut W; Dyer V; Pluda J M; Reed E
Drug-induced lupus associated with COL-3: report of 3 cases.
Archives of dermatology 2001;137(4):471-4.
2001: Blagosklonny M V; Dixon S C; Robey R; Figg W D
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.
International journal of oncology 2001;18(4):697-704.
2001: Burstein A H; Reed E; Tompkins A C; Venzon D; Figg W D
Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
Pharmacotherapy 2001;21(3):281-6.
2001: Dixon S C; Knopf K B; Figg W D
The control of prostate-specific antigen expression and gene regulation by pharmacological agents.
Pharmacological reviews 2001;53(1):73-91.
2001: Bartlett D L; Libutti S K; Figg W D; Fraker D L; Alexander H R
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Surgery 2001;129(2):176-87.
2001: Chico I; Kang M H; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg W D; Fojo T; Bates S
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):832-42.
2001: Sunwoo J B; Herscher L L; Kroog G S; Thomas G R; Ondrey F G; Duffey D C; Solomon B I; Boss C; Albert P S; McCullugh L; Rudy S; Muir C; Zhai S; Figg W D; Cook J A; Mitchell J B; Van Waes C
Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):800-11.
2001: Rudek M A; Figg W D; Dyer V; Dahut W; Turner M L; Steinberg S M; Liewehr D J; Kohler D R; Pluda J M; Reed E
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):584-92.
2000: Walther M M; Rehak N N; Venzon D; Myers C E; Linehan W M; Figg W D
Suramin administration is associated with a decrease in serum calcium levels.
World journal of urology 2000;18(6):388-91.
2000: Bauer K S; Lush R M; Rudek M A; Shih C; Sausville E; Figg W D
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomedical chromatography : BMC 2000;14(5):338-43.
2000: Little R F; Wyvill K M; Pluda J M; Welles L; Marshall V; Figg W D; Newcomb F M; Tosato G; Feigal E; Steinberg S M; Whitby D; Goedert J J; Yarchoan R
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(13):2593-602.
2000: Berger A C; Alexander H R; Tang G; Wu P S; Hewitt S M; Turner E; Kruger E; Figg W D; Grove A; Kohn E; Stern D; Libutti S K
Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Microvascular research 2000;60(1):70-80.
2000: Rudek M A; March C L; Bauer K S; Pluda J M; Figg W D
High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.
Journal of pharmaceutical and biomedical analysis 2000;22(6):1003-14.
2000: Kruger E A; Figg W D
TNP-470: an angiogenesis inhibitor in clinical development for cancer.
Expert opinion on investigational drugs 2000;9(6):1383-96.
2000: Berger A C; Feldman A L; Gnant M F; Kruger E A; Sim B K; Hewitt S; Figg W D; Alexander H R; Libutti S K
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.
The Journal of surgical research 2000;91(1):26-31.
2000: Messmann R A; Vitetta E S; Headlee D; Senderowicz A M; Figg W D; Schindler J; Michiel D F; Creekmore S; Steinberg S M; Kohler D; Jaffe E S; Stetler-Stevenson M; Chen H; Ghetie V; Sausville E A
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1302-13.
2000: Blagosklonny M V; Dixon S C; Figg W D
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
The Journal of urology 2000;163(3):1022-6.
2000: Wilson W H; Sorbara L; Figg W D; Mont E K; Sausville E; Warren K E; Balis F M; Bauer K; Raffeld M; Senderowicz A M; Monks A
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):415-21.
2000: Kruger E A; Duray P H; Tsokos M G; Venzon D J; Libutti S K; Dixon S C; Rudek M A; Pluda J; Allegra C; Figg W D
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Biochemical and biophysical research communications 2000;268(1):183-91.
2000: Bauer K S; Cude K J; Dixon S C; Kruger E A; Figg W D
Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.
The Journal of pharmacology and experimental therapeutics 2000;292(1):31-7.
1999: Bubley G J; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg W D; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak D P; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small E J; Smith M R; Trump D L; Wilding G
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3461-7.
1999: Kang M H; Figg W D; Dahut W
Taxanes in hormone-refractory prostate cancer.
Cancer practice 1999;7(5):270-2.
1999: Bergan R C; Reed E; Myers C E; Headlee D; Brawley O; Cho H K; Figg W D; Tompkins A; Linehan W M; Kohler D; Steinberg S M; Blagosklonny M V
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2366-73.
1999: Bauer K S; Figg W D; Hamilton J M; Jones E C; Premkumar A; Steinberg S M; Dyer V; Linehan W M; Pluda J M; Reed E
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2324-9.
1999: Cude K J; Dixon S C; Guo Y; Lisella J; Figg W D
The androgen receptor: genetic considerations in the development and treatment of prostate cancer.
Journal of molecular medicine (Berlin, Germany) 1999;77(5):419-26.
1999: Park B J; Brown C K; Hu Y; Alexander H R; Horti J; Raje S; Figg W D; Bartlett D L
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.
Human gene therapy 1999;10(6):889-98.
1999: Cho H K; Lush R M; Bartlett D L; Alexander H R; Wu P C; Libutti S K; Lee K B; Venzon D J; Bauer K S; Reed E; Figg W D
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Journal of clinical pharmacology 1999;39(4):394-401.
1999: Horti J; Dixon S C; Logothetis C J; Guo Y; Reed E; Figg W D
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.
British journal of cancer 1999;79(9-10):1588-93.
1999: Figg W D; Raje S; Bauer K S; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
Journal of pharmaceutical sciences 1999;88(1):121-5.
1999: Senderowicz A M; Reid R; Headlee D; Abornathy T; Horti J; Lush R M; Reed E; Figg W D; Sausville E A
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
1999: Arah I N; Dixon S C; Horti J; Figg W D
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Neoplasma 1999;46(2):117-23.
1999: Dixon S C; Kruger E A; Bauer K S; Figg W D
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.
Cancer chemotherapy and pharmacology 1999;43 Suppl():S78-84.
1998: Bauer K S; Kohn E C; Lush R M; Steinberg S M; Davis P; Kohler D; Reed E; Figg W D
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Journal of pharmacokinetics and biopharmaceutics 1998;26(6):673-87.
1998: Piscitelli S C; Vogel S; Figg W D; Raje S; Forrest A; Metcalf J A; Baseler M; Falloon J
Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Pharmacotherapy 1998;18(6):1212-6.
1998: Alexander H R; Brown C K; Bartlett D L; Libutti S K; Figg W D; Raje S; Turner E
Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2357-62.
1998: Bartlett D L; Buell J F; Libutti S K; Reed E; Lee K B; Figg W D; Venzon D J; Alexander H R
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Cancer 1998;83(6):1251-61.
1998: Senderowicz A M; Headlee D; Stinson S F; Lush R M; Kalil N; Villalba L; Hill K; Steinberg S M; Figg W D; Tompkins A; Arbuck S G; Sausville E A
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2986-99.
1998: Fuse E; Tanii H; Kurata N; Kobayashi H; Shimada Y; Tamura T; Sasaki Y; Tanigawara Y; Lush R D; Headlee D; Figg W D; Arbuck S G; Senderowicz A M; Sausville E A; Akinaga S; Kuwabara T; Kobayashi S
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Cancer research 1998;58(15):3248-53.
1998: Horti J; Figg W D; Weinberger B; Kohler D; Sartor O
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Oncology reports 1998;5(4):893-6.
1998: Bauer K S; Dixon S C; Figg W D
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.
Biochemical pharmacology 1998;55(11):1827-34.
1998: Welles L; Saville M W; Lietzau J; Pluda J M; Wyvill K M; Feuerstein I; Figg W D; Lush R; Odom J; Wilson W H; Fajardo M T; Humphrey R W; Feigal E; Tuck D; Steinberg S M; Broder S; Yarchoan R
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1112-21.
1998: Feuer J A; Lush R M; Venzon D; Duray P; Tompkins A; Sartor O; Figg W D
Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 1998;46(2):66-72.
1998: Thibault A; Figg W D; Bergan R C; Lush R M; Myers C E; Tompkins A; Reed E; Samid D
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.
Tumori 1998;84(1):87-9.
1998: Dawson N; Figg W D; Brawley O W; Bergan R; Cooper M R; Senderowicz A; Headlee D; Steinberg S M; Sutherland M; Patronas N; Sausville E; Linehan W M; Reed E; Sartor O
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):37-44.
1998: Dixon S C; Horti J; Guo Y; Reed E; Figg W D
Methods for extracting and amplifying genomic DNA isolated from frozen serum.
Nature biotechnology 1998;16(1):91-4.
1998: Kruger E A; Blagosklonny M V; Dixon S C; Figg W D
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.
Invasion & metastasis 1998;18(4):209-18.
1998: Sausville E A; Lush R D; Headlee D; Smith A C; Figg W D; Arbuck S G; Senderowicz A M; Fuse E; Tanii H; Kuwabara T; Kobayashi S
Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S54-9.
1997: Piscitelli S C; Figg W D; Hahn B; Kelly G; Thomas S; Walker R E
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 1997;41(12):2797-9.
1997: Walsh T J; Whitcomb P; Piscitelli S; Figg W D; Hill S; Chanock S J; Jarosinski P; Gupta R; Pizzo P A
Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
Antimicrobial agents and chemotherapy 1997;41(9):1944-8.
1997: Bergan R C; Walls R G; Figg W D; Dawson N A; Headlee D; Tompkins A; Steinberg S M; Reed E
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
Journal of the National Medical Association 1997;89(9):622-8.
1997: Figg W D; Feuer J A; Bauer K S
Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.
Cancer practice 1997;5(4):258-63.
1997: Senderowicz A M; Vitetta E; Headlee D; Ghetie V; Uhr J W; Figg W D; Lush R M; Stetler-Stevenson M; Kershaw G; Kingma D W; Jaffe E S; Sausville E A
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Annals of internal medicine 1997;126(11):882-5.
1997: Piscitelli S C; Forrest A; Lush R M; Ryan N; Whitfield L R; Figg W D
Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Pharmacotherapy 1997;17(3):431-7.
1997: Kohn E C; Figg W D; Sarosy G A; Bauer K S; Davis P A; Soltis M J; Thompkins A; Liotta L A; Reed E
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1985-93.
1997: Ma G Y; Bartlett D L; Reed E; Figg W D; Lush R M; Lee K B; Libutti S K; Alexander H R
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
The cancer journal from Scientific American 1997;3(3):174-9.
1997: Figg W D; Christian M C; Lush R; Link C J; Davis P; Kohn E; Sarosy G; Rothenberg M L; Weiss R B; Ryan N; Jacobs J; Reed E
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Biopharmaceutics & drug disposition 1997;18(4):347-59.
1997: Figg W D; Kroog G; Duray P; Walther M M; Patronas N; Sartor O; Reed E
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Cancer 1997;79(10):1964-8.
1997: Dawson N A; Figg W D; Cooper M R; Sartor O; Bergan R C; Senderowicz A M; Steinberg S M; Tompkins A; Weinberger B; Sausville E A; Reed E; Myers C E
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1470-7.
1997: Dixon S C; Zalles A; Giordano C; Lush R M; Venzon D; Reed E; Figg W D
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Cancer letters 1997;113(1-2):111-6.
1997: Lush R M; Meadows B; Fojo A T; Kalafsky G; Smith H T; Bates S; Figg W D
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Journal of clinical pharmacology 1997;37(2):123-8.
1997: Figg W D; Pluda J M; Lush R M; Saville M W; Wyvill K; Reed E; Yarchoan R
The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
Pharmacotherapy 1997;17(1):91-7.
1997: Dixon S C; Soriano B J; Lush R M; Borner M M; Figg W D
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.
The Annals of pharmacotherapy 1997;31(1):76-82.
1996: Boudoulas S; Lush R M; McCall N A; Samid D; Reed E; Figg W D
Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.
Therapeutic drug monitoring 1996;18(6):714-20.
1996: Lush R M; Figg W D; Pluda J M; Bitton R; Headlee D; Kohler D; Reed E; Sartor O; Cooper M R
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):939-44.
1996: Walls R; Thibault A; Liu L; Wood C; Kozlowski J M; Figg W D; Sampson M L; Elin R J; Samid D
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.
The Prostate 1996;29(3):177-82.
1996: Dawson N A; Lush R M; Steinberg S M; Tompkins A C; Headlee D J; Figg W D
Suramin-induced neutropenia.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1534-9.
1996: Stone M J; Sausville E A; Fay J W; Headlee D; Collins R H; Figg W D; Stetler-Stevenson M; Jain V; Jaffe E S; Solomon D; Lush R M; Senderowicz A; Ghetie V; Schindler J; Uhr J W; Vitetta E S
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood 1996;88(4):1188-97.
1996: Middleman M N; Lush R M; Figg W D
The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Pharmacotherapy 1996;16(3):376-81.
1996: Thibault A; Samid D; Tompkins A C; Figg W D; Cooper M R; Hohl R J; Trepel J; Liang B; Patronas N; Venzon D J; Reed E; Myers C E
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):483-91.
1996: Middleman M N; Lush R M; Sartor O; Reed E; Figg W D
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Cancer treatment reviews 1996;22(2):105-18.
1996: Tisdale J F; Figg W D; Reed E; McCall N A; Alkins B R; Horne M K
Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.
American journal of hematology 1996;51(2):152-7.
1996: Kohn E C; Reed E; Sarosy G; Christian M; Link C J; Cole K; Figg W D; Davis P A; Jacob J; Goldspiel B; Liotta L A
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Cancer research 1996;56(3):569-73.
1996: Bowden C J; Figg W D; Dawson N A; Sartor O; Bitton R J; Weinberger M S; Headlee D; Reed E; Myers C E; Cooper M R
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Cancer chemotherapy and pharmacology 1996;39(1-2):1-8.
1996: Figg W D; Ammerman K; Patronas N; Steinberg S M; Walls R G; Dawson N; Reed E; Sartor O
Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.
Cancer investigation 1996;14(6):513-7.
1996: Figg W D; Dawson N; Middleman M N; Brawley O; Lush R M; Senderowicz A; Steinberg S H; Tompkins A; Reed E; Sartor O
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(6):763-5.
1996: Walther M M; Figg W D; Linehan W M
Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
World journal of urology 1996;14 Suppl 1():S8-11.
1995: Bitton R J; Figg W D; Venzon D J; Dalakas M C; Bowden C; Headlee D; Reed E; Myers C E; Cooper M R
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2223-9.
1995: Figg W D; Cole K A; Reed E; Steinberg S M; Piscitelli S C; Davis P A; Soltis M J; Jacob J; Boudoulas S; Goldspiel B
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):797-803.
1995: Dawson N A; Cooper M R; Figg W D; Headlee D J; Thibault A; Bergan R C; Steinberg S M; Sausville E A; Myers C E; Sartor O
Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Cancer 1995;76(3):453-62.
1995: Sausville E A; Headlee D; Stetler-Stevenson M; Jaffe E S; Solomon D; Figg W D; Herdt J; Kopp W C; Rager H; Steinberg S M
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Blood 1995;85(12):3457-65.
1995: Thibault A; Samid D; Cooper M R; Figg W D; Tompkins A C; Patronas N; Headlee D J; Kohler D R; Venzon D J; Myers C E
Phase I study of phenylacetate administered twice daily to patients with cancer.
Cancer 1995;75(12):2932-8.
1995: Piscitelli S C; Thibault A; Figg W D; Tompkins A; Headlee D; Lieberman R; Samid D; Myers C E
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
Journal of clinical pharmacology 1995;35(4):368-73.
1995: Figg W D; Sartor O; Cooper M R; Thibault A; Bergan R C; Dawson N; Reed E; Myers C E
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
The American journal of medicine 1995;98(4):412-4.
1995: Figg W D; Thibault A; Cooper M R; Reid R; Headlee D; Dawson N; Kohler D R; Reed E; Sartor O
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Cancer 1995;75(8):2159-64.
1995: Bitton R J; Figg W D; Reed E
A preliminary risk-benefit assessment of paclitaxel.
Drug safety : an international journal of medical toxicology and drug experience 1995;12(3):196-208.
1994: Foss F M; Borkowski T A; Gilliom M; Stetler-Stevenson M; Jaffe E S; Figg W D; Tompkins A; Bastian A; Nylen P; Woodworth T
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Blood 1994;84(6):1765-74.
1994: Figg W D; Cooper M R; Thibault A; Headlee D; Humphrey J; Bergan R C; Reed E; Sartor O
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Cancer 1994;74(5):1612-4.
1994: Figg W D; Walls R G; Cooper M R; Thibault A; Sartor O; McCall N A; Myers C E; Samid D
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.
Anti-cancer drugs 1994;5(3):336-42.
1994: Figg W D; Thibault A; Sartor A O; Mays D; Headlee D; Calis K A; Cooper M R
Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.
Archives of internal medicine 1994;154(9):1023-5.
1994: Thibault A; Cooper M R; Figg W D; Venzon D J; Sartor A O; Tompkins A C; Weinberger M S; Headlee D J; McCall N A; Samid D
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Cancer research 1994;54(7):1690-4.
1994: Figg W D; Yeh H J; Thibault A; Pluda J M; Itoh F; Yarchoan R; Cooper M R
Assay of the antiangiogenic compound TNP-470, and one of its metabolites, AGM-1883, by reversed-phase high-performance liquid chromatography in plasma.
Journal of chromatography 1994;652(2):187-94.
1994: Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg W D; Linehan W M; Myers C E
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Journal of the National Cancer Institute 1994;86(3):222-7.
1993: Thibault A; Figg W D; Cooper M R; Prindiville S A; Sartor A O; Headlee D J; Myers C E
Anaphylactoid reaction with suramin.
Pharmacotherapy 1993;13(6):656-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

William Figg

Research Profile (preview)

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of William Figg (preview)

All Publications